Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has appointed veteran life sciences executive David Gill as a Non-Executive Director, effective May 11, 2026, as part of a broader board expansion and succession plan. Gill, who has extensive experience in biopharmaceuticals, radiopharmaceuticals and U.S. capital markets, is expected to become Chair in due course, succeeding Mark Nelson, who will remain on the board.
The company also announced that Genevieve Ryan has resigned as Company Secretary, with Shomalin Naidoo stepping in on an interim basis while a permanent replacement is recruited. These governance changes signal Telix’s effort to strengthen its board and corporate oversight in line with its growth trajectory and obligations as a dual-listed company.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, it operates across the U.S., Europe, Japan, Brazil, Canada and the U.K., and is dual-listed on the ASX and Nasdaq, underscoring its international capital markets focus.
Average Trading Volume: 3,078,644
Technical Sentiment Signal: Hold
Current Market Cap: A$4.63B
Learn more about TLX stock on TipRanks’ Stock Analysis page.